Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;31(10):2475-2489.
doi: 10.1681/ASN.2020050564. Epub 2020 Sep 22.

Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup

Collaborators, Affiliations

Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup

Ingrid Berling et al. J Am Soc Nephrol. 2020 Oct.

Abstract

Background: Although chloroquine, hydroxychloroquine, and quinine are used for a range of medical conditions, recent research suggested a potential role in treating COVID-19. The resultant increase in prescribing was accompanied by an increase in adverse events, including severe toxicity and death. The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup sought to determine the effect of and indications for extracorporeal treatments in cases of poisoning with these drugs.

Methods: We conducted systematic reviews of the literature, screened studies, extracted data, and summarized findings following published EXTRIP methods.

Results: A total of 44 studies (three in vitro studies, two animal studies, 28 patient reports or patient series, and 11 pharmacokinetic studies) met inclusion criteria regarding the effect of extracorporeal treatments. Toxicokinetic or pharmacokinetic analysis was available for 61 patients (13 chloroquine, three hydroxychloroquine, and 45 quinine). Clinical data were available for analysis from 38 patients, including 12 with chloroquine toxicity, one with hydroxychloroquine toxicity, and 25 with quinine toxicity. All three drugs were classified as non-dialyzable (not amenable to clinically significant removal by extracorporeal treatments). The available data do not support using extracorporeal treatments in addition to standard care for patients severely poisoned with either chloroquine or quinine (strong recommendation, very low quality of evidence). Although hydroxychloroquine was assessed as being non-dialyzable, the clinical evidence was not sufficient to support a formal recommendation regarding the use of extracorporeal treatments for this drug.

Conclusions: On the basis of our systematic review and analysis, the EXTRIP workgroup recommends against using extracorporeal methods to enhance elimination of these drugs in patients with severe chloroquine or quinine poisoning.

Keywords: COVID-19; Chloroquine; Hydroxychloroquine; Quinine; hemodialysis; hemofiltration.

PubMed Disclaimer

Figures

None
Graphical abstract
Figure 1.
Figure 1.
The litterature search last performed on January 15th, 2020, after removal of duplicates and non-pertinent records, yielded 44 studies for analysis. No comparative observational studies or randomized trials were identified. EAPCCT, European Association of Poisons Centres and Clinical Toxicologists; NACCT, North American Congress of Clinical Toxicology; PK, pharmacokinetic.

References

    1. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. : Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 56: 105949, 2020. - PMC - PubMed
    1. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D: Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 55: 105932, 2020. - PMC - PubMed
    1. Borba MGS, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, Brito M, et al. : Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A randomized clinical trial. JAMA Netw Open 3: e208857, 2020 - PubMed
    1. Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. : Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19 [published online ahead of print June 5, 2020]. Med doi:10.1016/j.medj.2020.06.001 - PMC - PubMed
    1. Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. : The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 26: 808–809, 2020 - PubMed

Publication types

MeSH terms